Evidence map›Paper›PMID 35675927›Full record

ArticleSaudi medical journal2022

Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination.

Abdullah Algaissi, Edrous Alamer, Mohammed Jeraiby, Abeer Alomaish, Omer Elrhima, Sultan Qumayi, Naaif A Qasir, Halima Areeshi, Asma Masmali, Abdulaziz Alhazmi

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Abdullah AlgaissiFrom the Department of Medical Laboratories Technology (Algaissi, Alamer, Qasir), College of Applied Medical Sciences; form the Department of Emerging and Epidemic Infectious Diseases Research Unit (Algaissi, Alamer, Jeraiby, Alomaish, Qumayi, Qasir, Areeshi, Masmali, Alhazmi) Medical Research Center; from the Department of Biochemistry (Jeraiby); from the Department of Pathology (Elrhima); Department of Microbiology and Parasitology (Alhazmi), College of Medicine, Jazan University, Jazan, Kingdom of Saudi Arabia.
Edrous AlamerFrom the Department of Medical Laboratories Technology (Algaissi, Alamer, Qasir), College of Applied Medical Sciences; form the Department of Emerging and Epidemic Infectious Diseases Research Unit (Algaissi, Alamer, Jeraiby, Alomaish, Qumayi, Qasir, Areeshi, Masmali, Alhazmi) Medical Research Center; from the Department of Biochemistry (Jeraiby); from the Department of Pathology (Elrhima); Department of Microbiology and Parasitology (Alhazmi), College of Medicine, Jazan University, Jazan, Kingdom of Saudi Arabia.
Mohammed JeraibyFrom the Department of Medical Laboratories Technology (Algaissi, Alamer, Qasir), College of Applied Medical Sciences; form the Department of Emerging and Epidemic Infectious Diseases Research Unit (Algaissi, Alamer, Jeraiby, Alomaish, Qumayi, Qasir, Areeshi, Masmali, Alhazmi) Medical Research Center; from the Department of Biochemistry (Jeraiby); from the Department of Pathology (Elrhima); Department of Microbiology and Parasitology (Alhazmi), College of Medicine, Jazan University, Jazan, Kingdom of Saudi Arabia.
Abeer AlomaishFrom the Department of Medical Laboratories Technology (Algaissi, Alamer, Qasir), College of Applied Medical Sciences; form the Department of Emerging and Epidemic Infectious Diseases Research Unit (Algaissi, Alamer, Jeraiby, Alomaish, Qumayi, Qasir, Areeshi, Masmali, Alhazmi) Medical Research Center; from the Department of Biochemistry (Jeraiby); from the Department of Pathology (Elrhima); Department of Microbiology and Parasitology (Alhazmi), College of Medicine, Jazan University, Jazan, Kingdom of Saudi Arabia.
Omer ElrhimaFrom the Department of Medical Laboratories Technology (Algaissi, Alamer, Qasir), College of Applied Medical Sciences; form the Department of Emerging and Epidemic Infectious Diseases Research Unit (Algaissi, Alamer, Jeraiby, Alomaish, Qumayi, Qasir, Areeshi, Masmali, Alhazmi) Medical Research Center; from the Department of Biochemistry (Jeraiby); from the Department of Pathology (Elrhima); Department of Microbiology and Parasitology (Alhazmi), College of Medicine, Jazan University, Jazan, Kingdom of Saudi Arabia.
Sultan QumayiFrom the Department of Medical Laboratories Technology (Algaissi, Alamer, Qasir), College of Applied Medical Sciences; form the Department of Emerging and Epidemic Infectious Diseases Research Unit (Algaissi, Alamer, Jeraiby, Alomaish, Qumayi, Qasir, Areeshi, Masmali, Alhazmi) Medical Research Center; from the Department of Biochemistry (Jeraiby); from the Department of Pathology (Elrhima); Department of Microbiology and Parasitology (Alhazmi), College of Medicine, Jazan University, Jazan, Kingdom of Saudi Arabia.
Naaif A QasirFrom the Department of Medical Laboratories Technology (Algaissi, Alamer, Qasir), College of Applied Medical Sciences; form the Department of Emerging and Epidemic Infectious Diseases Research Unit (Algaissi, Alamer, Jeraiby, Alomaish, Qumayi, Qasir, Areeshi, Masmali, Alhazmi) Medical Research Center; from the Department of Biochemistry (Jeraiby); from the Department of Pathology (Elrhima); Department of Microbiology and Parasitology (Alhazmi), College of Medicine, Jazan University, Jazan, Kingdom of Saudi Arabia.
Halima AreeshiFrom the Department of Medical Laboratories Technology (Algaissi, Alamer, Qasir), College of Applied Medical Sciences; form the Department of Emerging and Epidemic Infectious Diseases Research Unit (Algaissi, Alamer, Jeraiby, Alomaish, Qumayi, Qasir, Areeshi, Masmali, Alhazmi) Medical Research Center; from the Department of Biochemistry (Jeraiby); from the Department of Pathology (Elrhima); Department of Microbiology and Parasitology (Alhazmi), College of Medicine, Jazan University, Jazan, Kingdom of Saudi Arabia.
Asma MasmaliFrom the Department of Medical Laboratories Technology (Algaissi, Alamer, Qasir), College of Applied Medical Sciences; form the Department of Emerging and Epidemic Infectious Diseases Research Unit (Algaissi, Alamer, Jeraiby, Alomaish, Qumayi, Qasir, Areeshi, Masmali, Alhazmi) Medical Research Center; from the Department of Biochemistry (Jeraiby); from the Department of Pathology (Elrhima); Department of Microbiology and Parasitology (Alhazmi), College of Medicine, Jazan University, Jazan, Kingdom of Saudi Arabia.
Abdulaziz AlhazmiFrom the Department of Medical Laboratories Technology (Algaissi, Alamer, Qasir), College of Applied Medical Sciences; form the Department of Emerging and Epidemic Infectious Diseases Research Unit (Algaissi, Alamer, Jeraiby, Alomaish, Qumayi, Qasir, Areeshi, Masmali, Alhazmi) Medical Research Center; from the Department of Biochemistry (Jeraiby); from the Department of Pathology (Elrhima); Department of Microbiology and Parasitology (Alhazmi), College of Medicine, Jazan University, Jazan, Kingdom of Saudi Arabia.
Atacama Large Millimeter Submillimeter Array · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate hematological parameters and thrombotic profiles of healthy individuals who received Pfizer-BioNTech (BNT162b2) vaccines in Saudi Arabia.

methodsHematological parameters and the incidence of anti-platelet factor-4 (anti/PF-4) antibodies were evaluated in 40 participants who were eligible for COVID-19 vaccination in Saudi Arabia (above 18 years old) at Jazan University Hospital. These parameters were assessed at 2 different timepoints; at day 0 (the day of receiving the first dose of Pfizer- BioNTech (BNT162b2) and prior to vaccination) and 14-21 days after receiving the vaccine.

resultsAmong the participants, 38 (80%) were men, while 12 (20%) were women, with a mean age of 27 years. A total of 15% of the participants reported previous infection with SARS-CoV-2 and 3 patients had a history of diabetes mellitus and hypertension. Hematological parameters results in those vaccines showed no significant changes between the 2 timepoints, such as, day 0 (just before receiving vaccination) and 14 to 21 days post vaccination. Further, anti/PF4 antibodies were negative for all participants following vaccination.

conclusionOur data showed that the incidence of hematological abnormalities or induction of anti/PF4 antibodies following Pfizer-BioNTech (BNT162b2) vaccination is not common, which is consistent with several previous reports. However, larger studies with more participants evaluated at different timepoints following vaccination are warranted to exclude potential transient hematological abnormalities.

Indexed as

COVID-19ThrombocytopeniaViral VaccinesAdolescentAdultBNT162 VaccineCOVID-19 VaccinesFemaleHumansMaleSARS-CoV-2VaccinationBNT162 VaccineCOVID-19 VaccinesViral VaccinesCOVID-19COVID-19 pandemicPfizer-BioNTechplateletsSARS-CoV-2thrombocytopeniavaccine

Identifiers

PMID35675927
PMCPMC9389887
OpenAlexW4281687967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.